Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.

Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, Kleiner D, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN)..

Aliment Pharmacol Ther. 2010 Nov;32(9):1174-83. doi: 10.1111/j.1365-2036.2010.04449.x. Epub 2010 Sep 3.

2.

Case report: fulminant hepatic failure involving duloxetine hydrochloride.

Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB.

Clin Gastroenterol Hepatol. 2006 Jul;4(7):912-7. Epub 2006 Jun 22.

PMID:
16797245
3.

Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M.

Dig Dis Sci. 2013 Jun;58(6):1766-75. doi: 10.1007/s10620-012-2553-1. Epub 2013 Feb 2.

4.

Clinical and histologic features of azithromycin-induced liver injury.

Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, Gu J, Hoofnagle JH, Chalasani N.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):369-376.e3. doi: 10.1016/j.cgh.2014.07.054. Epub 2014 Aug 9.

5.

Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.

Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network..

J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):182-9. doi: 10.1097/MPG.0b013e31821d6cfd.

6.

The hepatic safety profile of duloxetine: a review.

McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, Alsuwaidan M, Soczynska JK, Lourenco MT, Konarski JZ, Kennedy SH.

Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):281-5. doi: 10.1517/17425255.4.3.281 . Review.

PMID:
18363543
7.

Answers to the most common questions about the hepatic safety profile of duloxetine.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, Regev A, Wernicke JF.

Postgrad Med. 2008 Jul;120(2):111-8. doi: 10.3810/pgm.2008.07.1803. Review.

PMID:
18654076
8.

Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL.

Hepatology. 2014 Aug;60(2):679-86. doi: 10.1002/hep.27157. Epub 2014 May 13.

9.

Clinical and histopathologic features of fluoroquinolone-induced liver injury.

Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH; DILIN Research Group..

Clin Gastroenterol Hepatol. 2011 Jun;9(6):517-523.e3. doi: 10.1016/j.cgh.2011.02.019. Epub 2011 Feb 26.

10.

Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events.

Wernicke J, Acharya N, Strombom I, Gahimer JL, D'Souza DN, DiPietro N, Uetrecht JP.

Curr Drug Saf. 2008 May;3(2):143-53. Review.

PMID:
18690992
11.

[Mirtazapine-associated hepatotoxicity].

Rodriguez-Pecci MS, Fuente-Aguado Jde L, Montero-Tinnirello J, Fernandez-Fernandez FJ.

Med Clin (Barc). 2010 Nov 6;135(13):625-6. doi: 10.1016/j.medcli.2009.08.002. Epub 2009 Oct 12. Spanish. No abstract available.

PMID:
19822332
12.

Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP.

Curr Drug Saf. 2008 May;3(2):132-42. Review. Erratum in: Curr Drug Saf. 2009 Jan;4(1):94.

PMID:
18690991
13.

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J; United States Drug Induced Liver Injury Network..

Gastroenterology. 2015 Jun;148(7):1340-52.e7. doi: 10.1053/j.gastro.2015.03.006. Epub 2015 Mar 6.

14.

Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.

Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN)..

Hepatology. 2014 Feb;59(2):661-70. doi: 10.1002/hep.26709. Epub 2013 Dec 18.

15.

[Clinical and pathological features in 138 cases of drug-induced liver injury].

Lai RT, Wang H, Gui HL, Ye MZ, Dai WJ, Xiang XG, Zhao GD, Wang WJ, Xie Q.

Zhonghua Gan Zang Bing Za Zhi. 2012 Mar;20(3):185-9. doi: 10.3760/cma.j.issn.1007-3418.2012.03.009. Chinese.

PMID:
22475136
16.

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; DILIN Study Group..

Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005.

17.

Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience.

Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N.

J Clin Gastroenterol. 2013 Jul;47(6):553-8. doi: 10.1097/MCG.0b013e318276bf00.

18.

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources.

Strombom I, Wernicke JF, Seeger J, D'Souza DN, Acharya N.

Curr Drug Saf. 2008 May;3(2):154-62.

PMID:
18690993
19.

Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation.

Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton MR.

Liver Transpl. 2012 Jul;18(7):803-10. doi: 10.1002/lt.23424.

20.

Antidepressant-induced liver injury: a review for clinicians.

Voican CS, Corruble E, Naveau S, Perlemuter G.

Am J Psychiatry. 2014 Apr;171(4):404-15. doi: 10.1176/appi.ajp.2013.13050709. Review.

PMID:
24362450

Supplemental Content

Support Center